FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2590649837> ?p ?o ?g. }

• W2590649837 abstract "Abstract Multiple myeloma remains one of the best indication for intensive chemotherapy followed by autologous hematopoietic stem cell transplantation (autoT). Intensive therapy followed by autologous transplantation is superior to conventional chemotherapy and it was demonstrated that two autoT were superior to one except for patients in very good partial response or in complete response after the first autotransplant. Peripheral blood stem cells (PBSC) can be used as well as bone marrow as HSC source with the same efficacy but very few data have been reported regarding PBSC recruitment. The main goal of our work was to study the impact on overall and event-free survival (OS and EFS) of PBSC recruitment using either growth factors (GF) alone (steady state) or chemotherapy followed by GF. Secondly, we performed a multivariate analysis studying influence on OS and EFS of sex, age, lines of therapy, pretransplant status, TBI, PBSC recruitment and number of autoT. We have analyzed 193 PBSC autoT (1 autoT=160, 2 autoT=33) performed for 160 MM patients [81 males and 71 females, mean age: 55 years (39–71)]. At diagnosis, 88 patients presented a MM Ig G (70k and 18l), 28 Ig A (16k and 12l), 3 Ig D (1k and 2l), 21 light chains k and 13 light chains l, 3 non secreting and 4 with plasmocyte leukemias. According to Durie and Salmon classification 75% of patients were in stage III, 15% in stage II and 10% in progressive I. Before transplantation, patients have received 1 line of poly-chemotherapy (n=141), 2 lines (n=15) or 3 lines (n=4) and 154 were evaluated for the response with 11 complete remission, 113 partial remission and 30 stable or evolutive disease just before transplant. As HSC (n=189), patients received PBSC which were recruited by GF alone (n=105) or cyclophosphamide+GF (n= 84). Conditioning (n=189),consisted in melphalan and TBI (n=51), melphalan alone (n=132), melphalan associated to cyclophosphamide or busulfan (n=6). We divided the population into 4 groups : group 1 who received one autoT of PBSC recruited by GF (n=76), group 2 one autoT of PBSC recruited by chemotherapy+GF (n=50), group 3 two autoT of PBSC recruited by GF (n=16) and group 4 two autoT of PBSC recruited by chemotherapy+GF (n=17). The median follow-up (FU) of the 4 groups were different with shorter FU (group 3: 9.9 months, group 4: 13 months) for patients who received tandem autoT because of the recent character of this strategy as compared to a long term follow-up for patients who received only one transplant (group 1: 35months, group 2: 55.3 months). Probabilities of OS and EFS at 2 years were 76% (95%CI 67–87) and 60% (95%CI 49.5–73) for group 1, 77% (95%CI 65–90.5) and 70% (95%CI 57.5–85) for group 2, 87.5% (95%CI 73–100) and 72.9% (95%CI 49–100) for group 3, 100% and 66.7% (95%CI 36–100) for group 4. The difference was not significant because of follow-up differences between the 4 groups and small number of patients in groups 3 and 4. In addition, multivariate analysis did not show any significant influence of the different studied parameters on OS and EFS. Nevertheless, because of these interesting preliminary results, a longer follow-up is warranted for definitive conclusions." @default.
• W2590649837 created "2017-03-03" @default.
• W2590649837 creator A5005045049 @default.
• W2590649837 creator A5007908757 @default.
• W2590649837 creator A5024404992 @default.
• W2590649837 creator A5026018104 @default.
• W2590649837 creator A5052966035 @default.
• W2590649837 creator A5055128673 @default.
• W2590649837 creator A5059755273 @default.
• W2590649837 creator A5068217025 @default.
• W2590649837 creator A5070792872 @default.
• W2590649837 creator A5072027146 @default.
• W2590649837 creator A5072721892 @default.
• W2590649837 creator A5082189560 @default.
• W2590649837 creator A5087870886 @default.
• W2590649837 date "2004-11-16" @default.
• W2590649837 modified "2023-10-14" @default.
• W2590649837 title "Impact of Peripheral Blood Stem Cell Recruitment on Outcome of Single or Double Autologous Hematopoietic stem Cell Transplantation for Multiple Myeloma." @default.
• W2590649837 doi "https://doi.org/10.1182/blood.v104.11.5221.5221" @default.
• W2590649837 hasPublicationYear "2004" @default.
• W2590649837 type Work @default.
• W2590649837 sameAs 2590649837 @default.
• W2590649837 citedByCount "0" @default.
• W2590649837 crossrefType "journal-article" @default.
• W2590649837 hasAuthorship W2590649837A5005045049 @default.
• W2590649837 hasAuthorship W2590649837A5007908757 @default.
• W2590649837 hasAuthorship W2590649837A5024404992 @default.
• W2590649837 hasAuthorship W2590649837A5026018104 @default.
• W2590649837 hasAuthorship W2590649837A5052966035 @default.
• W2590649837 hasAuthorship W2590649837A5055128673 @default.
• W2590649837 hasAuthorship W2590649837A5059755273 @default.
• W2590649837 hasAuthorship W2590649837A5068217025 @default.
• W2590649837 hasAuthorship W2590649837A5070792872 @default.
• W2590649837 hasAuthorship W2590649837A5072027146 @default.
• W2590649837 hasAuthorship W2590649837A5072721892 @default.
• W2590649837 hasAuthorship W2590649837A5082189560 @default.
• W2590649837 hasAuthorship W2590649837A5087870886 @default.
• W2590649837 hasConcept C109159458 @default.
• W2590649837 hasConcept C126322002 @default.
• W2590649837 hasConcept C141071460 @default.
• W2590649837 hasConcept C143998085 @default.
• W2590649837 hasConcept C2776364478 @default.
• W2590649837 hasConcept C2776694085 @default.
• W2590649837 hasConcept C2777408962 @default.
• W2590649837 hasConcept C2778684742 @default.
• W2590649837 hasConcept C2779050716 @default.
• W2590649837 hasConcept C2780007613 @default.
• W2590649837 hasConcept C28328180 @default.
• W2590649837 hasConcept C2911091166 @default.
• W2590649837 hasConcept C54355233 @default.
• W2590649837 hasConcept C71924100 @default.
• W2590649837 hasConcept C86803240 @default.
• W2590649837 hasConcept C90924648 @default.
• W2590649837 hasConceptScore W2590649837C109159458 @default.
• W2590649837 hasConceptScore W2590649837C126322002 @default.
• W2590649837 hasConceptScore W2590649837C141071460 @default.
• W2590649837 hasConceptScore W2590649837C143998085 @default.
• W2590649837 hasConceptScore W2590649837C2776364478 @default.
• W2590649837 hasConceptScore W2590649837C2776694085 @default.
• W2590649837 hasConceptScore W2590649837C2777408962 @default.
• W2590649837 hasConceptScore W2590649837C2778684742 @default.
• W2590649837 hasConceptScore W2590649837C2779050716 @default.
• W2590649837 hasConceptScore W2590649837C2780007613 @default.
• W2590649837 hasConceptScore W2590649837C28328180 @default.
• W2590649837 hasConceptScore W2590649837C2911091166 @default.
• W2590649837 hasConceptScore W2590649837C54355233 @default.
• W2590649837 hasConceptScore W2590649837C71924100 @default.
• W2590649837 hasConceptScore W2590649837C86803240 @default.
• W2590649837 hasConceptScore W2590649837C90924648 @default.
• W2590649837 hasLocation W25906498371 @default.
• W2590649837 hasOpenAccess W2590649837 @default.
• W2590649837 hasPrimaryLocation W25906498371 @default.
• W2590649837 hasRelatedWork W1818467446 @default.
• W2590649837 hasRelatedWork W1997006795 @default.
• W2590649837 hasRelatedWork W2353124159 @default.
• W2590649837 hasRelatedWork W2386230525 @default.
• W2590649837 hasRelatedWork W2414051711 @default.
• W2590649837 hasRelatedWork W2432246041 @default.
• W2590649837 hasRelatedWork W2582431155 @default.
• W2590649837 hasRelatedWork W2944683649 @default.
• W2590649837 hasRelatedWork W3031522679 @default.
• W2590649837 hasRelatedWork W3031694499 @default.
• W2590649837 isParatext "false" @default.
• W2590649837 isRetracted "false" @default.
• W2590649837 magId "2590649837" @default.
• W2590649837 workType "article" @default.